Claims
- 1. A benzonorbornene derivative of formula (I) or an isomer or salt thereof having the formula ##STR42## wherein R.sub.1, R.sub.3 and R.sub.4 each independently represent hydrogen, C.sub.1 -C.sub.8 alkoxy, halogen, C.sub.1 -C.sub.8 alkyl, C.sub.1 -C.sub.8 acycloxy or hydroxyl,
- R' is hydrogen or C.sub.1 -C.sub.6 alkyl and
- R is hydrogen, C.sub.1 -C.sub.6 alkyl, --SR.sub.5, --SOR.sub.5 or --SO.sub.2 R.sub.5, wherein R.sub.5 is C.sub.1 -C.sub.6 alkyl.
- 2. The benzonorbornene derivative of claim 1 selected from the group consisting of
- trans-5,8-methano-5,6,7,8-tetrahydro-2-(.beta.-methylstyrl) naphthalene,
- trans-5,8-methano-5,6,7,8-tetrahydro-2-(4'-methyl-.beta.-methylstyrl) naphthalene and
- trans-5,8-methano-5,6,7,8-tetrahydro-2-(4'-methylsulphonyl-.beta.-methylstyrl) naphthalene.
- 3. A composition suitable for pharmaceutical use comprising, in a pharmaceutically acceptable carrier, at least one benzonorbornene derivative of claim 1.
- 4. The composition of claim 3 in a form suitable for topical administration, wherein said benzonorbornene derivative is present in an amount ranging from 0.005 to 2 percent by weight of said composition.
- 5. The composition of claim 4 wherein said benzonorbornene derivative is present in an amount ranging from 0.002 to 1 percent by weight of said composition.
- 6. The composition of claim 4 in the form of an ointment, gel, cream, pomade, powder, tincture, solution, suspension, emulsion, lotion, spray, patch or saturated pad.
- 7. The composition of claim 3 in a form suitable for enteral administration.
- 8. The composition of claim 3 in a form suitable for oral administration.
- 9. The composition of claim 3 in the form of a solution or suspension suitable for parenteral administration.
- 10. The composition of claim 9 wherein said benzonorbornene derivative is present in an amount ranging from 0.01 to 1 mg per ml of said solution or suspension.
- 11. The composition of claim 3 in a form suitable for ocular administration.
- 12. The composition of claim 3 wherein said pharmaceutically acceptable carrier is at least one of water, gelatin, lactose, starch, talc, liquid petrolatum, gum arabic, polyalkylene glycol and magnesium stearate.
- 13. The composition of claim 3 which also includes, as an inert or pharmacodynamically active additive, one or more of a hydrating agent, at antiseborrhoeic agent, an antibiotic, an anti=acne agent, an agent promoting regrowth of hair, an anti-inflammatory agent, a carotenoid, a antipsoriatic agent, an flavoring agent, a preservative, a stabilizer, a moisture-regulating agent, a pH-regulating agent, an osmotic pressure modifying agent, a UV-A or UV-B screening agent or an antioxidant.
- 14. A cosmetic composition comprising in a cosmetically acceptable carrier at least one benzonorbornene derivative of claim 1.
- 15. The cosmetic composition of claim 14 wherein said benzonorbornene derivative is present in an amount ranging from 0.005 to 2 percent by weight of said composition.
- 16. The cosmetic composition of claim 15 wherein said benzonorbornene derivative is present in an amount ranging from 0.01 to 1 percent by weight of said composition.
- 17. The cosmetic composition of claim 14 in the form of a lotion, a gel, a cream, a soap or a shampoo.
- 18. The cosmetic composition of claim 14 which also includes as an inert or cosmetically active additive, one or more of a hydrating agent, an antiseborrheic agent, an antibiotic, an anti-acne agent, an agent promoting growth of hair, an anti-inflammatory agent, a carotenoid, an antipsoriatic agent, a flavoring agent, a preservative, a stabilizer, a moisture-regulating agent, a pH-regulating agent, an osmotic pressure modifying agent or an antioxidant.
- 19. A method for the treatment of a dermatological complaint connected with a keratinization (differentiation-proliferation) disorder, of dermatological or other complaints with an inflammatory and/or immuno-allergic component, of benign or malignant dermatological proliferations, of rheumatoid psoriasis or of ophthalmological complaints, which comprises administering to a subject suffering therefrom or liable thereto an effective amount of the benzonorbornene derivative of claim 1.
- 20. The method of claim 19 wherein from 2 mg to 2 g of said derivative is administered per day per kg of body weight.
- 21. The benzonorbornene of claim 1, which is trans-5,8-methano-5,6,7,8-tetrahydro-2-(.beta.-methylstyryl) naphthalene.
Priority Claims (2)
Number |
Date |
Country |
Kind |
85531 |
Sep 1984 |
LUX |
|
85700 |
Dec 1984 |
LUX |
|
Parent Case Info
This is a continuation of application Ser. No. 07/218,204, filed July 13, 1988, now U.S. Pat. No. 4,931,589, which is a continuation of Ser. No. 06/772,525, filed Sep. 4, 1985, now U.S. Pat. No. 4,783,549.
Foreign Referenced Citations (1)
Number |
Date |
Country |
8500806 |
Feb 1985 |
WOX |
Non-Patent Literature Citations (1)
Entry |
Dawson, M., et al., J. Med. Chem. 27(11)1516-31, 1984. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
218204 |
Jul 1988 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
772525 |
Sep 1985 |
|